FasoracetamvsLemon Balm

Fasoracetam upregulates GABA-B receptor (GABA-B1/GABA-B2 heterodimer) expression and function, which is unique among racetams — this receptor upregulation is potentially beneficial for restoring GABAergic sensitivity after prolonged benzodiazepine or phenibut use. It enhances group II metabotropic glutamate receptor (mGluR2/mGluR3) signaling, which modulates presynaptic glutamate release and reduces excitotoxicity. Fasoracetam increases acetylcholine release in the cerebral cortex via modulation of choline acetyltransferase activity and vesicular acetylcholine transporter function. It may also modulate the glutamatergic system through mGluR5. The combination of GABAergic (GABA-B-mediated inhibition), glutamatergic (mGluR modulation), and cholinergic enhancement provides anxiolytic effects alongside cognitive enhancement. Clinical trials focus on ADHD patients with GRM (glutamate receptor) gene variants.

Lemon balm inhibits GABA-transaminase (GABA-T), the enzyme that converts GABA to succinic semialdehyde in the GABA shunt, increasing GABA availability in synaptic terminals and producing anxiolytic effects via GABA-A (alpha2, alpha3 subunits) and GABA-B receptors. Rosmarinic acid provides antioxidant effects via Nrf2 activation and anti-inflammatory effects through COX-2 and NF-kB inhibition. Lemon balm inhibits acetylcholinesterase (AChE) at the catalytic site, mildly increasing acetylcholine in the hippocampus and cortex — explaining cognitive enhancement at moderate doses via muscarinic M1 and nicotinic receptor activation. At higher doses, GABAergic effects dominate, producing sedation useful for sleep. Additional mechanisms may include 5-HT2A antagonism and muscimol-like GABA-A modulation from trace constituents.